Find your next paid study

Jonsson Comprehensive Cancer CenterNCT07439484

Observational

Herbal Formula Ma-Zi-Ren-Wan (MZRW) on Bowel Movement Function and Gut Microbiome Among Cancer Survivors With Constipation: A Double-blinded Randomized Controlled Trial (RELIEVE)

The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with pl…

ConstipationCancerFunctional Constipation

Memorial Sloan Kettering Cancer CenterNCT07091084

Refractory Metastatic Colorectal Cancer

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients With Refractory Metastatic Colorectal Cancer With Liver Dominant Disease

The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patien…

Delcath Systems Inc.NCT06607458

~$10 – $8,750

Adenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma+2 more

A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma

The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX)…

Memorial Sloan Kettering Cancer CenterNCT05672524

Phase 3

A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of pr…

Metastatic Non-small Cell Lung Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more

~$10 – $7,500

AstraZenecaNCT06417814

Phase 1

Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

This phase I trial tests the safety, side effects, and best dose of ASTX727 when given in combination with a usual approach of treatment with paclitaxel and pe…

National Cancer Institute (NCI)NCT05673200

~$10 – $5,625

Phase II Study to Examine Precision Radiation in Patients With Pathogenic Mutations in ATM

This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the l…

Metastatic Cancer

Memorial Sloan Kettering Cancer CenterNCT05010031

Non-Small Cell Lung CancerNSCLCAdvanced Non-Small Cell Lung Cancer+1 more

Phase 2 Study to Evaluate Reduced Dose Chemotherapy in Combination With Anti-PD-1 Therapy as First Line Treatment in Vulnerable or Older Adults (Vulnerable or Age ≥70) With Advanced PD-L1 TPS <50% Non-small Cell Lung Cancer

Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patien…

Virginia Commonwealth UniversityNCT06731413

Decision Counseling and Follow-up (DCaF) for Shield+ Patients

Prospective, observational, minimal-risk study evaluating decision-making, decisional conflict, intention to undergo complete diagnostic evaluation (CDE), and …

Colo-rectal Cancer

Guardant Health, Inc.NCT07620535

~$10 – $1,050

Phase 1

Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC).…

Locally Advanced Triple Negative Breast CancerTNBC - Triple-Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma

~$10 – $7,500

Rima PatelNCT06637306

Phase 1

[18F]FTT Positron Emission Tomography (PET) in Patients With Metastatic Breast Cancer

This clinical trial studies how well fluorine F 18 fluorthanatrace (\[18F\]FTT) positron emission tomography (PET) works in imaging patients with breast cancer…

University of WashingtonNCT06502691

Phase 4

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan…

Prostate Cancer